[PDF][PDF] Guidelines for the diagnosis, prevention and management of osteoporosis

…, G Osella, M Pedrazzoni, L Sinigaglia, O Viapiana… - …, 2016 - research.unipd.it
On behalf of the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)
with the endorsement of Italian Society of Endocrinology (SIE) Italian Society of …

Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study

…, V Braga, M Rossini, L Tatò, O Viapiana… - Journal of Bone and …, 2005 - academic.oup.com
In a randomized controlled study, we investigated the effect of treatment with intravenous
neridronate in prepubertal children with OI. Our study suggests that quarterly intravenous …

The obesity paradox and osteoporosis

…, D Gatti, G Adami, A Giollo, O Viapiana - Eating and Weight …, 2018 - Springer
Overweight and obesity according to the definition of the WHO are considered as an
abnormal or excessive fat accumulation that may impair health. Studies comparing fracture …

Relationship between serum parathyroid hormone, vitamin D sufficiency, age, and calcium intake

S Adami, O Viapiana, D Gatti, L Idolazzi, M Rossini - Bone, 2008 - Elsevier
Vitamin D deficiency is extremely common among elderly subjects and it has been
associated with poor bone health, and to a number of other conditions. The ideal 25-hydroxy-vitamin …

[HTML][HTML] Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial

…, I Prevete, L Sinigaglia, M Valenti, O Viapiana… - PLoS …, 2019 - journals.plos.org
Background The inflammatory contribution to type 2 diabetes (T2D) has suggested new
therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we …

[HTML][HTML] Osteoporosis in rheumatic diseases

…, C Caimmi, A Giollo, G Orsolini, O Viapiana… - International journal of …, 2019 - mdpi.com
Osteoporosis is a chronic disease characterized by an increased risk of fragility fracture.
Patients affected by rheumatic diseases are at greater risk of developing osteoporosis. The …

Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis

…, D Schena, D Vecchiato, M Bonifacio, O Viapiana… - Bone, 2011 - Elsevier
OBJECTIVE: We systematically assessed bone mineral density (BMD), bone turnover markers
(BTM), and fractures in a large cohort of patients with Indolent Systemic Mastocytosis (ISM)…

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study

…, G Lopalco, R Cimaz, F Cantini, O Viapiana… - Clinical …, 2016 - Springer
Growing data have provided encouraging results on the use of interleukin (IL)-1 inhibitors in
Behçet’s disease (BD). This study was aimed at reporting the largest experience with anti-IL-…

Osteoporosis in 10 years time: a glimpse into the future of osteoporosis

G Adami, A Fassio, D Gatti, O Viapiana… - Therapeutic …, 2022 - journals.sagepub.com
Patients living with osteoporosis are projected to increase dramatically in the next decade.
Alongside the forecasted increased societal and economic burden, we will live a crisis of …

Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab

D Gatti, O Viapiana, E Fracassi… - Journal of Bone and …, 2012 - academic.oup.com
The bone mass benefits of antiresorbers in postmenopausal osteoporosis are limited by the
rapid coupling of decreasing bone resorption with bone formation. Wnt signaling is involved …